Pressure BioSciences, Inc. Well Positioned to Play Important Role in US's $1.8 Billion "Cancer Moonshot" Initiative
Bill Signed Into Law Earlier this Week Offers the Potential to Completely Transform Cancer ResearchPressure BioSciences, Inc. Reports Third Quarter 2016 Financial Results and Provides Business Update
Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" or the "Company") today announced financial results for the third quarter ended September 30, 2016, and provided a business update.Pressure BioSciences, Inc. Closes $2,000,000 Line-of-Credit
Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" and the "Company"), a leader in the development and sale of broadly enabling constant pressure and pressure cycling technology ("PCT")-based sample preparation solutions to the large and growing worldwide life sciences industry, today announced it has closed a $2 million line-of-credit with an accredited investor.SECFilings.com Reports on Pressure BioSciences' Q1 2016 Financial Results
SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, takes a deeper dive into Pressure BioSciences Inc.'s (OTCQB:PBIO) recently filed first quarter 2016 financial results.Pressure BioSciences, Inc. Reports First Quarter 2016 Financial Results and Provides Business Update
Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" or the "Company") today announced financial results for the 2016 first quarter ended March 31, 2016, provided a business update, and offered limited guidance for the remainder of FY2016.